Recent News

• 06.09.2026 - iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
• 05.13.2026 - IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
• 05.06.2026 - iMDx to Release First Quarter 2026 Results on May 13, 2026
• 04.14.2026 - Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay
• 03.26.2026 - IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Recent Filings

• 05.13.2026 - 8-K/A Current report
• 05.13.2026 - 8-K Current report
• 05.13.2026 - EX-99.1 EX-99.1
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.30.2026 - ARS Annual Report to Security Holders
• 04.30.2026 - 8-K Current report
• 04.27.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.27.2026 - 4 Statement of changes in beneficial ownership of securities